Translational Development Acquisition (TDAC) Preferred Stock Liabilities (2024 - 2026)
Translational Development Acquisition's (TDAC) quarterly Preferred Stock Liabilities came in at $183.3 million in Q1 2026, up 4.02% YoY from $176.2 million in Q1 2025, and up 0.89% on a QoQ basis from $181.7 million in Q4 2025.
Translational Development Acquisition (TDAC) Preferred Stock Liabilities (2024 - 2026) Analysis & Trends
Translational Development Acquisition (TDAC) has 3 years of Preferred Stock Liabilities data on file, last reported at $183.3 million in Q1 2026.
- Quarterly Preferred Stock Liabilities rose 4.02% year-over-year to $183.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $183.3 million (up 4.02% YoY) and the FY2025 annual result came in at $181.7 million, up 4.19% from the prior year.
- Preferred Stock Liabilities rose to $183.3 million in Q1 2026, from $181.7 million in the prior quarter.
- In the past five years, Preferred Stock Liabilities ranged from a high of $183.3 million in Q1 2026 to a low of $174.4 million in Q4 2024.
- A 3-year average of $178.9 million and a median of $179.0 million in 2025 frame the typical range for Preferred Stock Liabilities.
- Annual changes were most pronounced in 2025 — Preferred Stock Liabilities climbed 4.19% — and 2026, when it gained 4.02%.
- Tracing TDAC's Preferred Stock Liabilities over 3 years: stood at $174.4 million in 2024, then gained by 4.19% to $181.7 million in 2025, then grew by 0.89% to $183.3 million in 2026.
- The last three Preferred Stock Liabilities figures came in at $183.3 million (Q1 2026), $181.7 million (Q4 2025), and $179.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oxley Bridge Acquisition | 585.76 Mn | 585.76 Mn | - | 260.50 Mn |
| 2 | Launch Two Acquisition | 557.86 Mn | 557.86 Mn | - | 245.51 Mn |
| 3 | Drugs Made In America Acquisition | 507.00 Mn | 507.00 Mn | - | 513.88 Mn |
| 4 | Cantor Equity Partners IV | 468.00 Mn | 468.00 Mn | - | 464.77 Mn |
| 5 | GP-Act III Acquisition | 401.06 Mn | 401.06 Mn | - | 98.24 Mn |
| 6 | Aldel Financial | 397.49 Mn | 397.49 Mn | - | 247.40 Mn |
| 7 | Republic Digital Acquisition | 389.25 Mn | 388.51 Mn | - | 313.51 Mn |
| 8 | Gores Holdings X | 385.06 Mn | 384.87 Mn | - | 373.78 Mn |
| 9 | Agriculture & Natural Solutions Acquisition | 377.29 Mn | 377.04 Mn | - | 376.71 Mn |
| 10 | Translational Development Acquisition | 182.66 Mn | 182.57 Mn | - | 157.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 183.27 Mn |
| Dec 31, 2025 | 181.66 Mn |
| Sep 30, 2025 | 179.90 Mn |
| Jun 30, 2025 | 178.03 Mn |
| Mar 31, 2025 | 176.18 Mn |
| Dec 31, 2024 | 174.35 Mn |